CytoDyn (OTCMKTS:CYDY – Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04, Zacks reports.
CytoDyn Stock Up 2.7%
CYDY opened at $0.21 on Friday. CytoDyn has a one year low of $0.18 and a one year high of $0.40. The stock’s 50 day moving average price is $0.21 and its 200-day moving average price is $0.25.
CytoDyn Company Profile
CytoDyn Inc is a biotechnology company focused on the development of leronlimab, an investigational monoclonal antibody that targets CCR5, a receptor involved in immune-cell signaling and the movement of certain cells through the body. The company’s research has explored potential applications in infectious diseases, oncology and inflammatory conditions.
Leronlimab, also known as PRO 140, has been studied primarily as a potential treatment for HIV infection, including in combination with existing antiretroviral therapies.
Further Reading
- Five stocks we like better than CytoDyn
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
